RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition by Han, Wanting, Liu, Mingyu, Han, Dong, Li, Muqing, Toure, Anthia A., Wang, Zifeng, Besschetnova, Anna, Patalano, Susan, Macoska, Jill A., Gao, Shuai, He, Housheng Hansen, Cai, Changmeng

Get full text

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer by Han, Wanting, Liu, Mingyu, Han, Dong, Toure, Anthia A., Li, Muqing, Besschetnova, Anna, Wang, Zifeng, Patalano, Susan, Macoska, Jill A., Lam, Hung-Ming, Corey, Eva, He, Housheng Hansen, Gao, Shuai, Balk, Steven P., Cai, Changmeng

Get full text

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations by Weisberg, Ellen, Meng, Chengcheng, Case, Abigail E., Tiv, Hong L., Gokhale, Prafulla C., Toure, Anthia A., Buhrlage, Sara, Liu, Xiaoxi, Wang, Jinhua, Gray, Nathanael, Stone, Richard, Adamia, Sophia, Winer, Eric, Sattler, Martin, Griffin, James D.

Get full text

Abstract 2509: RB1 -loss in castration-resistant prostate cancer reprograms androgen receptor signaling and confers vulnerability to LSD1 inhibition by Han, Wanting, Liu, Mingyu, Han, Dong, Li, Muqing, Toure, Anthia A., Patalano-Salsman, Susan C., Macoska, Jill A., Gao, Shuai, Cai, Changmeng

Get full text

BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma by Weisberg, Ellen, Chowdhury, Basudev, Meng, Chengcheng, Case, Abigail E., Ni, Wei, Garg, Swati, Sattler, Martin, Azab, Abdel Kareem, Sun, Jennifer, Muz, Barbara, Sanchez, Dana, Toure, Anthia, Stone, Richard M., Galinsky, Ilene, Winer, Eric, Gleim, Scott, Gkountela, Sofia, Kedves, Alexia, Harrington, Edmund, Abrams, Tinya, Zoller, Thomas, Vaupel, Andrea, Manley, Paul, Faller, Michael, Chung, BoYee, Chen, Xin, Busenhart, Philipp, Stephan, Christine, Calkins, Keith, Bonenfant, Debora, Thoma, Claudio R., Forrester, William, Griffin, James D.

Get full text